Form 4: Nuvalent Insider Sells Shares Under 10b5-1 Plan

Nuvalent, Inc. reports that Chief Development Officer Darlene Noci sold shares of Class A Common Stock as part of a pre-arranged trading plan.

Summary

• Darlene Noci, Chief Development Officer at Nuvalent, Inc., executed a series of transactions on May 28, 2026.
• These transactions involved the sale of Class A Common Stock and the acquisition of stock options.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 18, 2024.
• A total of 5,500 shares were acquired through the exercise of stock options at a price of $27.85 per share.
• Subsequently, 1,300 shares were sold at a weighted average price of $106.26, 1,422 shares at $107.33, 1,178 shares at $108.01, and 1,500 shares at $109.30, and 100 shares at $109.76.
• Following these transactions, Noci beneficially owns 58,117 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a pre-arranged Rule 10b5-1 plan and the profitable exercise of options mitigates significant concern.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impacting sales.
• The exercise of stock options at $27.85 and subsequent sale at significantly higher prices ($105.72 to $109.76) suggests a profitable outcome for the executive.
• The reporting person still holds a substantial number of shares (58,117) after the reported transactions.

Negatives

• A significant number of shares (6,500 in total from the weighted average sales) were disposed of by a key executive.
• The sales represent a divestment of company stock by an insider, which can sometimes be perceived negatively by the market.

Risks

• The Rule 10b5-1 plan is designed to mitigate insider trading concerns, but the sale of a large number of shares by an executive could still be interpreted as a lack of confidence in future stock performance by some investors.
• The weighted average sale prices indicate a range of market values at which the shares were sold, reflecting potential market volatility on the transaction date.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future financial performance. The future outlook is primarily inferred from the insider's trading plan and stock ownership.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) of this Form 4, upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event in the biotechnology sector as executives often diversify their holdings or monetize stock options. The significant difference between the option exercise price and the sale price suggests a successful outcome for the executive, which is typical for companies experiencing stock appreciation.

Stakeholder Impact

• Shareholders: May interpret insider selling as a potential negative signal, though the Rule 10b5-1 plan provides context. The profitable exercise of options by management could be seen as a positive indicator of past company performance.
• Employees: The stock options exercised and sold are part of employee compensation, and the executive's profitable transaction may reflect positively on the company's stock performance.
• Management: Darlene Noci successfully monetized stock options, demonstrating a positive return on her equity-based compensation.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for future transactions, if applicable.
• Potential future vesting and exercise of remaining stock options.
• Ongoing monitoring of Darlene Noci's beneficial ownership and any further transactions.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Darlene Noci, Beneficial Ownership, Securities Transaction